Back to Search Start Over

Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System.

Results from the First-in-Human Study of the Caterpillar™ Arterial Embolization System.

Authors :
Holden, Andrew
Mwipatayi, Bibombe P.
Khashram, Manar
Dubenec, Steven
Goh, Gerard S.
Settlage, Richard A.
Source :
CardioVascular & Interventional Radiology; Jan2023, Vol. 46 Issue 1, p100-111, 12p
Publication Year :
2023

Abstract

Purpose: To assess occlusion success and adverse events associated with the use of a self-expanding device for peripheral artery embolization. Methods: This prospective, single-arm, feasibility study was conducted using the Caterpillar™ Arterial Embolization Device composed of opposing nitinol fibers and a flow-occluding membrane. Twenty patients (24 embolization sites) were treated at four investigational centers in New Zealand and Australia and followed for 30 days. Embolization sites included mesenteric, accessory renal, and iliac arteries and their branches. Primary outcome measures were peri-procedural occlusion confirmed by angiography and freedom from device-related serious adverse events (SAEs) at 30 days. Secondary observations included time to occlusion and assessment of adverse events. Results: Peri-procedural occlusion was 100%, and freedom from a device-related SAE was 94.7% at 30 days. One patient had abdominal bloating that required hospitalization deemed possibly related to the device or procedure. Twenty-two of 24 embolization sites were occluded with one device (91.7%). Mean procedure duration was 11.7 ± 8.6 min (device deployment time: 1.8 ± 1.0 min), and mean fluoroscopy time was 241 ± 290.7 s. All embolization sites occluded during the procedure with 62.5% occluded within three minutes and 91.6% occluded within ten minutes. No devices migrated or required re-embolization. Freedom from device- and procedure-related adverse events was 84.2%. One patient died from aortic rupture during a subsequent adjunctive abdominal aortic endovascular procedure deemed unrelated to the embolization device or procedure. Conclusions: This first-in-human study of the Caterpillar embolization device achieved peri-procedural occlusion in all patients with a 94.7% freedom from device-related SAE at 30 days. Level of Evidence: Level 2b—prospective, multicenter, single-arm, first-in-human clinical study. Pre-specified endpoints were analyzed using descriptive statistics. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01741551
Volume :
46
Issue :
1
Database :
Complementary Index
Journal :
CardioVascular & Interventional Radiology
Publication Type :
Academic Journal
Accession number :
161119796
Full Text :
https://doi.org/10.1007/s00270-022-03300-1